|
rs200075329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study suggests that the ER S118P variant does not affect risk for breast cancer or hormone therapy resistance.
|
30560461 |
2019 |
|
rs3778609
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These SNPs were in high LD (r<sup>2</sup> > 0.9) with each other, with the top SNP, rs3778609, associated with breast cancer with an odds ratio (OR) and 95% confidence interval (95% CI) of 0.76 (0.70-0.84).
|
30642363 |
2019 |
|
rs760503206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Surveying a small set of CAFs from breast cancer</span> biopsies, we found that a relatively common single nucleotide polymorphism, which results in the expression of a GPER variant with the amino acid substitution P16L, is associated with the nuclear localization of GPER.
|
28596490 |
2017 |
|
rs1459132456
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To evaluate the role of this polymorphism as a risk factor for breast cancer in Kurdish patients and to investigate the possible association between Arg194Trp x-ray repair cross-complementing group 1 (XRCC1) gene polymorphisms with clinical and histopathological outcomes of patients with breast cancer.
|
27279507 |
2016 |
|
rs523736
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For overall breast cancer risk, three single-nucleotide polymorphisms (SNPs) in miRNA biogenesis genes DROSHA rs78393591 (OR = 0.69, 95 % CI: 0.55-0.88, P = 0.003), ESR1 rs523736 (OR = 0.88, 95 % CI: 0.82-0.95, P = 3.99 × 10(-4)), and ZCCHC11 rs114101502 (OR = 1.33, 95 % CI: 1.11-1.59, P = 0.002), and one SNP in primary miRNA sequence (rs116159732 in miR-6826, OR = 0.74, 95 % CI: 0.63-0.89, P = 0.001) were found to have significant associations in both discovery and validation phases.
|
27380242 |
2016 |
|
rs9479118
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the > 13-year-old group, the AA genotype at rs1062577, the GG genotype at rs2881766, and the CC genotype at rs9479118 increased breast cancer susceptibility.
|
26850117 |
2016 |
|
rs2273206
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ESR1, rs2881766, rs2077647, rs926778, and rs2273206 polymorphisms increased breast cancer risk, and rs3798377 decreased the risk in overall patients.
|
25323936 |
2015 |
|
rs926778
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the tumor subtypes, rs2881766 increased breast cancer risk manly in luminal A, HER2-overexpressing, and triple-negative subtypes except for luminal B subtype, and rs926778 increased the risk in luminal A and triple-negative subtypes.
|
25323936 |
2015 |
|
rs1207112399
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The G473A polymorphism (rs1800449) results in the Arg158Gln amino acid substitution in the LOX propeptide, compromises its tumour suppressive activity, and was associated with an increased breast cancer risk in a Chinese Han population.
|
25141126 |
2014 |
|
rs12525163
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Further, two SNPs independent of previously reported signals in ESR1 [rs12525163 odds ratio (OR) = 1.15, P = 4.9 × 10(-) (4)] and 19p13.1 (rs1864112 OR = 0.84, P = 1.8 × 10(-) (9)) were associated with TN breast cancer.
|
24325915 |
2014 |
|
rs3798758
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Breast cancer risk was significantly associated with three SNPs located at 6q25.1-rs9383935 in CCDC170 and rs2228480 and rs3798758 in ESR1-with variant allele attributed odds ratios (ORs) of 1.38 (95% confidence interval (CI): 1.20 to 1.57, P=2.21×10(-6)), 0.84 (95% CI: 0.72 to 0.98, P=0.025) and 1.19 (95% CI: 1.04 to 1.37, P=0.013), respectively.
|
25116933 |
2014 |
|
rs2747648
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the study was to analyze the impact of the rs2747648 genetic variant in the estrogen receptor alpha (ER1) gene affecting a putative miR-453-binding site on the risk of breast cancer in postmenopausal women.
|
22012767 |
2012 |
|
rs747099645
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A DNA bank of patients with gynecologic oncology, patients with breast cancer (n = 335), and healthy women (n = 530) was created, and the following single-nucleotide polymorphisms were examined: CYP1A1 M1 polymorphism, that is, T264-C transition in the 30-noncoding region; CYP1A2*1F polymorphism, that is, C734-A transversion in the CYP1A2 gene; C-T transition (Arg264Cys) in exon 7 of CYP19; and SULT1A1*2 polymorphism, that is, G638-A transition (Arg213His) in the SULT1A1 gene.
|
21977969 |
2012 |
|
rs7766585
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Potential association to breast cancer was identified for 15 SNPs and one of these SNPs (rs7766585 in ESR1) was found to associate strongly with breast cancer, OR 1.30 (95% CI 1.17-1.45; p-value 2.1 × 10(-6)), when tested in a verification panel consisting of 3,211 unique breast cancer cases and 4,223 unique controls from five European biobank cohorts.
|
21105050 |
2011 |
|
rs1455751791
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data suggest that ER-beta polymorphism in exon 7 codon 392 (C1176G) is correlated with various aspects of breast cancer and lymph node metastasis in our group of patients.
|
20604969 |
2010 |
|
rs3020314
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNP rs3020314, tagging a region of ESR1 intron 4, is associated with an increase in breast cancer susceptibility with a dominant mode of action in European populations.
|
19126777 |
2009 |
|
rs761843408
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In a large multiethnic case-control study, the G/A870 polymorphism conferred no significant risk for breast cancer overall or by stage or estrogen receptor (ER) status.
|
19287456 |
2009 |
|
rs767863538
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A three-member fingerprint of S100P-correlated genes, consisting of GPRC5A, FXYD3, and PYCARD, conferred poor outcome in multiple breast cancer data sets, irrespective of estrogen receptor status but dependent on tumor size (P < 0.01).
|
19789341 |
2009 |
|
rs2144025
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multi-locus analysis of five adjacent tagSNPs suggested a region in ESR1 (between rs3003925 and rs2144025) for association with breast cancer risk (p = 0.001), but the result did not withstand adjustment for multiple comparisons (p = 0.086).
|
18271972 |
2008 |
|
rs3003925
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multi-locus analysis of five adjacent tagSNPs suggested a region in ESR1 (between rs3003925 and rs2144025) for association with breast cancer risk (p = 0.001), but the result did not withstand adjustment for multiple comparisons (p = 0.086).
|
18271972 |
2008 |
|
rs201145204
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the 378Ser variant allele carriers, the 24Pro/Pro wild-type homozygote was associated with a significantly increased breast cancer risk (adjusted OR=1.81, 95% CI=1.11-2.95), but the subjects having 24Pro/Ser or Ser/Ser variant genotypes had a significantly decreased risk (adjusted OR=0.74, 95% CI=0.56-0.99).
|
17028982 |
2007 |
|
rs746432
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we investigated breast cancer risk associated with genotypes and haplotypes resulting from four ESR1 single nucleotide polymorphisms (SNPs), rs746432, rs2234693, rs9340799, and rs1801132.
|
17268813 |
2007 |
|
rs1364963022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no statistical difference in the C1qA[276A/G] allelic distribution between all subjects with breast cancer and controls.
|
16465510 |
2006 |
|
rs200282497
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no statistical difference in the C1qA[276A/G] allelic distribution between all subjects with breast cancer and controls.
|
16465510 |
2006 |
|
rs188957694
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The majority of spontaneous and DMBA-induced carcinomas and sarcomas from p53(R270H/+)WAPCre mice is estrogen receptor alpha positive, and expression profiles of genes also implicated in human breast cancer appear similarly altered.
|
16166291 |
2005 |